Conversely, inhibition of anti-apoptotic Bcl-2 proteins can sensitize CML progenitor cells to TKIs and other agents [12, 20, 21]. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.